Facebook Pixel Code
About Sickkids
About SickKids

Petros Pechlivanoglou, M.Sc., PhD

Research Institute
Scientist
Child Health Evaluative Sciences

University of Toronto
Assistant Professor
Institute of Health Policy, Management and Evaluation


Phone: 416-813-7654 (ext. 309484)
Email: petros.pechlivanoglou@sickkids.ca
Alternate Contact: Natasha Naraidoo
Alternate Phone: 416-813-7654 (ext. 309975)
Alternate Email: natasha.naraidoo@sickkids.ca

Brief Biography

Petros Pechlivanoglou, PhD, is a Scientist at The Hospital for Sick Children (SickKids) Research Institute and an Assistant Professor at the University of Toronto, Institute of Health Policy Management and Evaluation. He studied economics in his native country, Greece, econometrics at the University of Groningen, the Netherlands and obtained a PhD in health econometrics from the same university. He completed a post-doctoral fellowship at the University of Toronto, within the Toronto Health Economics and Technology Assessment (THETA) Collaborative where he focused on methodological aspects around the application of decision analysis in health-care policy.

Research Interests

  • Use of decision analysis in health care
  • Development of prediction models for economic evaluation
  • Application of evidence synthesis methods in health economics
  • Use of real-world evidence in economic evaluation

Research Activities

Pechlivanoglou's research activities currently are centred on the use of health decision analysis in economic evaluation; bridging evidence synthesis, administrative data and decision analysis; the application and extension of predictive models in health economics as well as other econometric and statistical applications in health economics and health policy, such as the estimation of empirical cost-effectiveness thresholds. He is currently involved in projects around the economics of pre-term birth prevention, the economic evaluation of oncology and ophthalmic interventions in children and adolescents and the economic impact of obstructive sleep apnea and COPD in adults.

Publications

For a complete list of publications, please visit PubMed.

Jalal H, Pechlivanoglou P, Krijkamp E, Alarid-Escudero F, Enns E, Hunink MG.  An overview of R in Health Decision Sciences. Med Decis Making. 2017 (Epub ahead of print)

Pechlivanoglou P, Abrahamyan L, MacKeigan L, Consiglio GP, Dolovich L, Li P, Cadarette SM, Rac VE, Shin J, Krahn M. Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in Ontario. BMC Health Services Research. 2016;21;16(1):666

Dolovich L, Consiglio G, MacKeigan L, Arahamyan L, Pechlivanoglou P, Rac VE, Pojskic N, Bojarski EA, Su J, Krahn M, Cadarette SM. Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013 CPJ. 2016;149(5): 293-302.

Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS,  Boon H, Huserau D, Pechlivanoglou P. Systematic review and network meta-analysis of stroke-prevention treatment in patients with atrial fibrillation Clinical Pharmacology: Advances and Applications. 2016;11(8):93-107.

Stevanović J, Pechlivanoglou P, Kampinga MA, Krabbe PF, Postma MJ. Multivariate Meta-analysis of preference-based quality of life values in coronary heart disease. PLoS One. 2016;24;11(3): E0152030

Tawfik A, Wodchis WP, Pechlivanoglou P, Hoch J, Husereau D, Krahn M. Using phase-based costing of real-world data to inform decision-analytic models for atrial fibrillation. Applied Health Economics and Health Policy, 2016;14(3):313-22

Abrahamyan L, Pechlivanoglou P, Krahn M, Carrasco-Labra A, Brignardello-Petersen R, Glick M, Guyatt GH, Azarpazhooh A. A practical approach to evidence-based dentistry: IX How to appraise and use an article about economic analysis. Journal of American Dental Association. 2015;146(9):679-689

Pechlivanoglou P, Yazew AF, Postma MJ, Wit E. An alternative parameterization of Bayesian logistic hierarchical models for mixed treatment comparisons. Pharmaceutical statistics 2015;14(4):322-31. 

Darvishian M, Gefenaite G, Turner RM, Pechlivanoglou P, Van der Hoek W, Van den Heuvel ER, Hak E. After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly. J Clin Epidemiol. 2014;67(7):734-744

Pechlivanoglou P, Wieringa JE, Jager T, Postma MJ. The effect of financial and educational incentives on rational prescribing. A state-space approach. Health Economics. 2015;24(4):439-53.

Stevanovic J, O'Prinsen AC, Postma MJ, Pechlivanoglou P. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension. A scenario analysis for the Netherlands. Clinical Therapeutics. 2014;36(3):368-84

Pechlivanoglou P. Le HH Daenen S, Postma MJ. Mixed treatment comparison (MTC) of antifungal prophylactic strategies against invasive fungal infections (IFIs) in patients receiving chemotherapy for haematological malignancies or allogeneic hematopoietic stem cells transplantation. JAC 2014;69(1):1-11

Mihajlović J, Pechlivanoglou P, Sabo A, Tomić Z, Postma MJ. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell cancer in Serbia. Clinical Therapeutic. 2013;35(12):1909-22. 

Mihajlović J, Pechlivanoglou P, Miladinov-Mikov M, Zivković S, Postma MJ. Cancer incidence and mortality in Serbia 1999-2009. BMC Cancer. 2013;13:18

Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, et al. The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases. 2013;32(3):305-16

Stevanovic J, Postma MJ, Pechlivanoglou P. A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention. European Journal of Preventive Cardiology. 2012;19(2(S)) 1–12

Pechlivanoglou P, van der Veen WJ, Bos JH, Postma MJ. Analyzing generic and branded substitution patterns in the Netherlands using prescription data. BMC Health Service Research. 2011;11:89

Pechlivanoglou P, De Vries R, Daenen S, Postma MJ. Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence. Pharmacoeconomics. 2011;29(9):737-751 

Luteijn JM, Hubben GA, Pechlivanoglou P, Bonten MJ, Postma MJ. Diagnostic accuracy of culture-based and PCR-based detection tests for MRSA – a meta-analysis. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases.2011;17(2):146-154.

Pechlivanoglou P, Vehof J, van Agthoven M, Postma MJ. Diffusion of a new drug: adoption, patients’ treatment complexity and persistence of risperidone long-acting injectable (RLAI). Clinical Therapeutics. 2010;32(1):108-18

Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, Pechlivanoglou P, van Toly FF, de Jong-van den Bert LTW, de Johg PE, Postma MJ, Prevention of Renal and Vascular End Stage disease Study Group. Cost effectiveness of population-based ‘screen-and-treat’ strategies for albuminuria to prevent cardiovascular and renal disease. Clinical Therapeutics. 2010;32(6):1103-1121 

Hubben GA, Bishai D, Pechlivanoglou P, Cattelan AM, Grisetti R, Facchin C, Compostella FA, Bos JM, Postma MJ, Tramarin A. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life. AIDS Care. 2008;20(4):449-55.